Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure

Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure

This study sought to determine whether the sodium/glucose cotransporter 2 (SGLT2) inhibitor empagliflozin improved heart failure (HF) outcomes in nondiabetic mice. The EMPA-REG OUTCOME (Empagliflozin, Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) trial demonstrated that em...

Full description

Bibliographic Details
Main Authors: Nikole J. Byrne, BSc, Nirmal Parajuli, PhD, Jody L. Levasseur, BSc, Jamie Boisvenue, BTech, Donna L. Beker, Grant Masson, BSc, Paul W.M. Fedak, MD, PhD, Subodh Verma, MD, PhD, Jason R.B. Dyck, PhD
Format: Article
Language:English
Published: Elsevier 2017-08-01
Series:JACC: Basic to Translational Science
Subjects:
empagliflozin
heart failure
SGLT2
sodium/glucose cotransporter 2 inhibitor
Online Access:http://www.sciencedirect.com/science/article/pii/S2452302X17301481

Similar Items

Similar Items